PimozideThird Party Manufacturing in India

Pimozide works by blocking dopamine D2 and D3 receptors in the brain, reducing the overactivity of dopaminergic pathways that contribute to tics and psychotic symptoms. As a potent centrally-acting dopamine receptor antagonist belonging to the diphenylbutylpiperidine class, pimozide binds to these receptors without activating them, preventing dopamine from exerting its effects. This antagonism is most pronounced in the mesolimbic pathway, where excessive dopamine activity is linked to the positive symptoms of psychosis such as hallucinations and delusions. In Tourette syndrome, modulation of dopaminergic activity in the basal ganglia helps suppress both motor and vocal tics. Pimozide also demonstrates affinity for serotonin 5-HT2A and 5-HT2C receptors, which may contribute to its therapeutic profile. Unlike haloperidol, pimozide has a longer half-life of approximately 55 hours in adults, allowing for once-daily dosing. It is extensively metabolised in the liver primarily through CYP3A4 with contributions from CYP1A2 and CYP2D6. Pimozide is reserved for patients whose tics severely compromise daily function and who have not responded adequately to standard treatment.

Therapeutic Uses

Pimozide is prescribed for the treatment of:

• Tourette Syndrome: Suppression of severe motor and phonic tics in patients with Tourette disorder who have failed to respond satisfactorily to standard treatment such as haloperidol.
• Delusional Infestation (Off-label): Used for delusional parasitosis where patients hold a fixed false belief of being infested with parasites.
• Schizophrenia (Off-label): Symptomatic management of psychotic disorders, though other antipsychotics are generally preferred due to pimozide's safety profile.

Why Manufacturers Choose Pimozide

Pimozide occupies a small but stable niche in the Indian psychiatric market as a second-line treatment for Tourette syndrome. While its prescription volume is lower than mainstream antipsychotics, pimozide commands higher per-unit pricing because it serves a specialised patient population with limited therapeutic alternatives. Relatively few domestic manufacturers produce this molecule, offering reduced competitive pressure and stronger pricing power. The tablet formulation is straightforward using conventional wet granulation technology, and the API is available through regulated supply chains. Demand comes primarily from neurology and psychiatry departments in tertiary care hospitals across India.

This makes Pimozide one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.